Can calcium and vitamin D supplementation adequately treat most patients with osteoporosis?
Deal
C
C
Department of Rheumatic and Immunologic Disease, Cleveland Clinic, USA. dealc@ccf.org
D000367:Age Factors; D015519:Bone Density / Q000187:drug effects*; D002117:Calcitriol / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002762:Cholecalciferol / Q000627:therapeutic use*; D019587:Dietary Supplements; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D014808:Vitamin D Deficiency / Q000097:blood / Q000188:drug therapy
D002121:Calcium Channel Blockers; D020845:Selective Estrogen Receptor Modulators; D002762:Cholecalciferol; D002117:Calcitriol; D002118:Calcium